Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 13/20 | 0.54 |
| ▸ | CTSD | P07339 | 1/20 | 0.52 |
| ▸ | REN | P00797 | 1/20 | 0.51 |
| ▸ | CDYL2 | Q8N8U2 | 1/20 | 0.50 |
| ▸ | CDYL | Q9Y232 | 1/20 | 0.50 |
| ▸ | GNPAT | O15228 | 1/20 | 0.48 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.47 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30799534 | 0.92 | BACE1 (0.62) | BACE1CTSD | |
| SCHEMBL30799675 | 0.91 | BACE1 (0.58) | BACE1CTSDCDYL2CDYL | |
| SCHEMBL30799455 | 0.91 | BACE1 (0.61) | BACE1CTSD | |
| SCHEMBL30799860 | 0.90 | BACE1 (0.57) | BACE1CTSDCDYL2CDYLOPRM1 | |
| SCHEMBL30799614 | 0.89 | BACE1 (0.51) | BACE1CTSD | |
| SCHEMBL30799790 | 0.88 | BACE1 (0.63) | BACE1CTSDOPRM1OPRD1 | |
| SCHEMBL30799630 | 0.87 | BACE1 (0.66) | BACE1CTSD | |
| SCHEMBL30799485 | 0.86 | OPRM1 (0.57) | BACE1CTSDRENCDYL2CDYL | |
| SCHEMBL29657465 | 0.86 | BACE1 (0.56) | BACE1CTSD | |
| SCHEMBL31181232 | 0.85 | BACE1 (0.53) | BACE1CTSDGNPAT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240116985-A1 | STAPLED PEPTIDES AND METHODS THEREOF | PARABILIS MEDICINES, INC. | 2024-04-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240116985-A1 | STAPLED PEPTIDES AND METHODS THEREOF | CTNNB1, APC, CTNNA1 | BACE1 10/4885CTSD 2704/4885REN 818/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.